Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Bacterial vaccines in development 1
Published on September 30, 2015 20 min
Other Talks in the Series: Vaccines
Bacterial vaccines in development 2
- Dr. Kathrin Jansen
- Pfizer Vaccine Research & Development, USA
Regulatory considerations for vaccine development: talk 1 - chemistry, manufacturing and control
- Dr. Norman W. Baylor
- Biologics Consulting Group, Inc., USA
DR. KATHRIN U. JANSEN: Hello. My name is Kathrin Jansen. I'm a Senior Vice President at Pfizer, responsible for vaccine research and development. Today, I will discuss bacterial vaccines in development.
Today's lecture is intended to give you a brief overview of licensed bacterial vaccines, and some examples of bacterial vaccines in development, to discuss key principles of bacterial vaccine design and development, to share with you some insights in the R&D efforts to develop bacterial vaccines. And I will be using three examples. The examples I have chosen are programs that my colleagues and I are working on at Pfizer. So they are real life examples of bacterial vaccine development. Specifically, we will touch on vaccines in development to protect against toxin-mediated diseases. The example is Clostridium difficile. We will touch on vaccines in development to protect against a very complex organism. The example is staphylococcus aureus, where the disease is mediated by the bacterium itself, and the virulence factors that it expresses. And finally, we will discuss recently licenced vaccines to protect the gram-negative bacterium, Neisseria meningitidis serogroup B.
Vaccines to prevent human bacterial diseases have been developed in some form or another since the 19th century. Louis Pasteur was the first to develop several bacterial vaccines against fowl cholera, anthrax, and human cholera. As you know, Leon Charles Albert Calmette and Jean-Marie Camille Guerin developed the first vaccine against TB. Effective anti-toxin antibody preparations against bacteria causing diphtheria and tetanus were produced by Emil von Behring and Shibasaburo Kitasato in the 1930s. And vaccines against these bacterial diseases were developed that have greatly reduced the morbidity and mortality associated with these bacterial pathogens. The first polysaccharide vaccines were introduced in the 1970s against Haemophilus influenza type B, Neisseria meningitidis, and streptococcus pneumoniae. Over the last decade and a half, glyco-conjugate vaccines have been developed for these pathogens to protect against the most prevalent strains of streptococcus pneumoniae, and Neisseria meningiditis. And these vaccines are significantly more immunogenic, particularly in young children, because the polysaccharide conjugate vaccines induce immune memory. Vaccines against these bacterial diseases have been exquisitely effective and have saved millions of lives globally since their introduction and widespread use. Despite these considerable advances however, a lot remains to be done. And there're still many important bacterial pathogens for which lifesaving vaccines are not yet available.